PIK3CA and prostate carcinoma: Here, for the first time in prostate cancer, we investigated the efficacy of a novel multikinase PIM/PI3K/mTOR inhibitor AUM302 and a combination of AZD-1208 and BEZ235, well-researched inhibitors of PIM and PI3K/mTOR, respectively.